Clinical Trial Update: Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma [Phase 1]

View source ↗

Summary

This clinical-trial update reports the completion of a Phase 1 study evaluating a combination of vorinostat and isotretinoin in patients with high-risk refracto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• ISOTRETINOIN (Isotretinoin)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma | Phase 1 | Status: COMPLETED